Summary
– Transaction expands Formation Bio’s immunology pipeline with Phase 1 ready drug candidate NEW YORK and SAN RAFAEL, Calif., July 29, 2025 /PRNewswire/ — Formation Bio, an AI-native pharma company, and IMIDomics, a precision medicine company focused on immune-mediated inflammatory…
Source: Pr Newswire
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
